ARTICLE | Clinical News
Durvalumab regulatory update
December 12, 2016 10:29 PM UTC
AstraZeneca said FDA accepted and granted Priority Review to a BLA for durvalumab to treat locally advanced or metastatic urothelial carcinoma in patients who have progressed after 1 standard platinum...
BCIQ Company Profiles
BCIQ Target Profiles